Last updated on November 2018

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline a Taxane and Capecitabine


Brief description of study

This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).

Detailed Study Description

This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).

In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle. In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.

This study will randomize approximately 220 patients using a 1:1 randomization ratio and stratification based on geographic region, tumor receptor status, and Eastern Cooperative Oncology Group (ECOG) status. At Screening, the Investigator must determine which TPC will be offered to the patient.

Data will be collected on subsequent anticancer therapies in both treatment groups from the time patients come off the study treatment until the time of primary data analysis for OS.

An independent data monitoring committee (DMC) will assess interim safety and efficacy data and determine final number of death events needed to provide 80% conditional power based on the zone adaptive design.

Clinical Study Identifier: NCT02915744

Contact Investigators or Research Sites near you

Start Over

Nektar Recruitment

Investigator Site - Tucson
Tucson, AZ United States
  Connect »

Nektar Recruitment

Investigator Site - Orange
Orange, CA United States
  Connect »

Nektar Recruitment

Investigator Site - San Francisco
San Francisco, CA United States
  Connect »

Nektar Recruitment

Investigator Site - Miami
Miami, FL United States
  Connect »

Nektar Recruitment

Investigator Site - Plantation
Plantation, FL United States
  Connect »

Nektar Recruitment

Investigator Site - West Palm Beach
West Palm Beach, FL United States
  Connect »

Nektar Recruitment

Investigator Site - Athens
Athens, GA United States
  Connect »

Nektar Recruitment

Investigator Site - Baltimore
Baltimore, MD United States
  Connect »

Nektar Recruitment

Investigator Site - Boston
Boston, MA United States
  Connect »

Nektar Recruitment

Investigator Site - Minneapolis
Minneapolis, MN United States
  Connect »

Nektar Recruitment

Investigator Site - Saint Louis
Saint Louis, MO United States
  Connect »

Nektar Recruitment

Investigator Site - New York
New York, NY United States
  Connect »

Nektar Recruitment

Investigator Site - Chapel Hill
Chapel Hill, NC United States
  Connect »

Nektar Recruitment

Investigator Site - Columbus
Columbus, OH United States
  Connect »

Nektar Recruitment

Investigator Site - Germantown
Germantown, TN United States
  Connect »

Nektar Recruitment

Investigator Site - Nashville
Nashville, TN United States
  Connect »

Nektar Recruitment

Investigator Site - Fort Worth
Fort Worth, TX United States
  Connect »

Nektar Recruitment

Investigator Site - Houston
Houston, TX United States
  Connect »

Nektar Recruitment

Investigator Site - Salt Lake City
Salt Lake City, UT United States
  Connect »

Nektar Recruitment

Investigator Site - Wollongong
Wollongong, Australia
  Connect »

Nektar Recruitment

Investigator Site - Brussels
Brussels, Belgium
  Connect »

Nektar Recruitment

Investigator Site - Charleroi
Charleroi, Belgium
  Connect »

Nektar Recruitment

Investigator Site - Grenoble
Grenoble, France
  Connect »

Nektar Recruitment

Investigator Site - Paris
Paris, France
  Connect »

Nektar Recruitment

Investigator Site - Rouen
Rouen, France
  Connect »

Nektar Recruitment

Investigator Site - Be'er Ya'aqov
Be'er Ya'aqov, Israel
  Connect »

Nektar Recruitment

Investigator Site - Beersheba
Beersheba, Israel
  Connect »

Nektar Recruitment

Investigator Site - Haifa
Haifa, Israel
  Connect »

Nektar Recruitment

Investigator Site - Jerusalem
Jerusalem, Israel
  Connect »

Nektar Recruitment

Investigator Site - Christchurch
Christchurch, New Zealand
  Connect »

Nektar Recruitment

Investigator Site - Barcelona
Barcelona, Spain
  Connect »

Nektar Recruitment

Investigator Site - Madrid
Madrid, Spain
  Connect »

Nektar Recruitment

Investigator Site - Santa Cruz de Tenerife
Santa Cruz de Tenerife, Spain
  Connect »

Nektar Recruitment

Investigator Site - Sevilla
Sevilla, Spain
  Connect »

Nektar Recruitment

Investigator Site - Manchester
Manchester, United Kingdom
  Connect »

Nektar Recruitment

Investigator Site - Seattle
Seattle, WA United States
  Connect »

Nektar Recruitment

Investigatory Site - Albury
Albury, Australia
  Connect »

Nektar Recruitment

Investigator Site - Darlinghurst
Darlinghurst, Australia
  Connect »

Nektar Recruitment

Investigator Site - Brisbane
Brisbane, Australia
  Connect »

Nektar Recruitment

Investigator Site - Subiaco
Subiaco, Australia
  Connect »

Nektar Recruitment

Investigator Site - Nedlands
Nedlands, Australia
  Connect »

Nektar Recruitment

Investigator Site - Edegem
Edegem, Belgium
  Connect »

Nektar Recruitment

Investigator Site - Namur
Namur, Belgium
  Connect »

Nektar Recruitment

Investigator Site - Sint-Niklaas
Sint-Niklaas, Belgium
  Connect »

Nektar Recruitment

Investigator Site - Praha
Praha, Czechia
  Connect »

Nektar Recruitment

Investigator Site - Le Mans
Le Mans, France
  Connect »

Nektar Recruitment

Investigator Site - Rennes
Rennes, France
  Connect »

Nektar Recruitment

Investigator Site - Saint-Cloud
Saint-Cloud, France
  Connect »

Nektar Recruitment

Investigator Site - Strasbourg
Strasbourg, France
  Connect »

Nektar Recruitment

Investigator Site - Toulouse
Toulouse, France
  Connect »

Nektar Recruitment

Investigator Site - Tel Aviv
Tel Aviv, Israel
  Connect »

Nektar Recruitment

Investigator Site - Milan
Milan, Italy
  Connect »

Nektar Recruitment

Investigator Site - Napoli
Napoli, Italy
  Connect »

Nektar Recruitment

Investigator Site - Lisbon
Lisbon, Portugal
  Connect »

Nektar Recruitment

Investigator Site - Porto
Porto, Portugal
  Connect »

Nektar Recruitment

Investigator Site - Granollers
Granollers, Spain
  Connect »

Nektar Recruitment

Investigator Site - Bradford
Bradford, United Kingdom
  Connect »

Nektar Recruitment

Investigator Site - Nottingham
Nottingham, United Kingdom
  Connect »

Nektar Recruitment

Investigator Site - Zerifin
Zerifin, Israel
  Connect »

Nektar Recruitment

Investigator Site - Milano
Milano, Italy
  Connect »

Nektar Recruitment

Investigator Site - Roma
Roma, Italy
  Connect »

Nektar Recruitment

Investigator Site - Liege
Liège, Belgium
  Connect »

Nektar Recruitment

Investigator Site - Montreal
Montréal, QC Canada
  Connect »

Nektar Recruitment

Investigator Site - Nimes
Nîmes, France
  Connect »

Nektar Recruitment

Investigator Site - San Sebasti n
San Sebastián, Spain
  Connect »

Nektar Recruitment

Investigator Site - Jaen
Jaén, Spain
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.